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T-segment elevation myocardial infarction (STEMI) is one of the greatest medical emergencies, for
hich organization of care has a determinant impact on patient outcomes. The purpose of this paper
s to review systems of care for STEMI patients. Although primary percutaneous coronary intervention
PCI) is the preferred option for patients with STEMI, offering easy and emergent access to this proce-
ure often remains difﬁcult because of geographic and diverse structural difﬁculties. intravenous ﬁbri-
olysis, especially when administered early after symptom onset and as part of a pharmacoinvasive
trategy (i.e., followed by rapid coronary angiography with PCI when necessary), offers a reasonable
herapeutic option in selected cases and has yielded satisfactory clinical results. Network organization
s central for optimizing patient care at the acute stage of myocardial infarction. This review describes
ifferent clinical experiences with network implementation both in Europe and in North America. In all
nstances, early recognition of STEMI and, particularly in the pre-hospital setting, shortening time de-
ays is central for the achievement of optimal clinical results. Overall, the encouraging results described
n the models presented here, as diverse as they might be, should be an encouragement to promote
nd implement regional protocols according to the speciﬁc local constraints and to monitor their ef-
ectiveness by recording simple quality indicators in ongoing registries. (J Am Coll Cardiol Intv 2009;
:901–8) © 2009 by the American College of Cardiology Foundationw
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oistorical Perspective
onsiderable progress has been made in the manage-
ent of patients with ST-segment elevation myocar-
ial infarction (STEMI) over the past 20 years. One
ajor step forward has been the recognition of the
athogenic role of thrombus leading to prolonged
cclusion of a coronary artery as the trigger of
yocardial infarction (MI) (1). Hence, much empha-
is has been put on reperfusion therapy, the role of
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fizer, Sanofi-Aventis, Servier, and The Medicines Company.t
anuscript received March 23, 2009; revised manuscript received May
8, 2009, accepted May 29, 2009.hich is to restore early coronary artery patency. The
rst methods of reperfusion were based on an invasive
pproach, and in the late 1970s, K. P. Rentrop was
he first to perform an invasive reperfusion therapy
ith mechanical recanalization during a complication
f coronary angiography; he subsequently added in-
racoronary fibrinolysis to mechanical recanalization,
orming the basis for the intracoronary thrombolytic
reatment of STEMI (2,3). The first trials of intra-
oronary streptokinase use in the 1980s showed a
eduction in infarct size as well as a decrease in
ortality (4). These trials led to the subsequent
ntravenous fibrinolysis trials, which were set up
ecause emergency coronary angiography seemed
ighly impractical at that time (5,6). Later on, there
as a first set of trials attempting to combine the best
f both worlds by using intravenous fibrinolytics first,
o gain time, followed by rapid coronary angioplasty;
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902nfortunately, these attempts at a combined pharmacoinvasive
trategy yielded poorer clinical results than intravenous fibri-
olysis as a stand-alone treatment and were rapidly abandoned
7). In the 1990s, the concept of primary angioplasty (i.e.,
oronary angioplasty not preceded by intravenous fibrinolytic
reatment) was developed, and randomized clinical trials con-
istently showed that this reperfusion technique was superior to
ntravenous fibrinolysis, making it the reference method of
eperfusion at the acute stage of MI (8,9). Practical consider-
tions remain, however, and we are still confronted with the
ecessity of finding a tailored approach for each patient and
efining systems of care appropriate for all. The goal of the
resent article is to describe where we currently stand in that
egard and what future directions might be taken to improve
hings further.
Summary of Recent Randomized Controlled
rials Comparing Primary PCI and
ntravenous Fibrinolysis
Fibrinolytic therapy versus pri-
mary PCI. The results from ran-
domized clinical trials have
formed the basis of the current
reperfusion practices and of in-
ternational and national guide-
lines (10,11). Keeley et al. (8)
performed a quantitative analysis
of 23 trials and demonstrated
that primary percutaneous coro-
nary intervention (PPCI) com-
pared with thrombolytic therapy
in STEMI patients resulted in
reduced mortality (7% vs. 9%,
p 0.0002), reinfarction (3% vs.
%, p  0.0001), stroke (1% vs. 2%, p  0.0004), and the
ombined end point of death, reinfarction, and stroke (8% vs.
4%, p  0.0001). Among these trials, the CAPTIM
Comparison of Angioplasty and Prehospital Thrombolysis
n Acute Myocardial Infarction) trial was the only one to
ompare PPCI and pre-hospital thrombolytic therapy, and
t was also the only one to find a trend toward reduced
ortality at 30 days and 1 year with pre-hospital fibrinolysis
ompared with PPCI (12). Conversely, comparing PPCI
ith thrombolytic treatment in patients admitted to hospi-
als without PCI capability showed a clear advantage of the
nterventional technique (9). In particular, the DANAMI-2
Danish Trial in Acute Myocardial Infarction-2) indicated
hat transferring a patient for PPCI (provided that the
ransfer took 2 h) was beneficial, particularly in terms of
einfarction, compared with treating with intravenous
hrombolytic therapy in the primary hospital (13,14).
In all these trials, however, the use of coronary angiog-
bbreviations
nd Acronyms
B  door-to-balloon
CG  electrocardiogram
ICU  mobile intensive
are unit
CI  percutaneous
oronary intervention
PCI  primary PCI
AMU  Service d’Aide
édicale Urgente
TEMI  ST-segment
levation myocardial
nfarctionaphy and angioplasty in fibrinolytic-treated patients was dimited to a minority, although there were large differences
etween trials: in CAPTIM, rescue PCI was performed in
6% of the patients receiving pre-hospital fibrinolysis,
hereas in DANAMI-2, only 1.9% of patients had a rescue
rocedure; for any subsequent PCI during the hospital stay,
he respective figures in the 2 trials were 34.5% and 16.4%
12,13).
CI after ﬁbrinolytic treatment. In spite of the disappointing
esults achieved with angioplasty after intravenous fibrino-
ysis in the late 1980s, new attempts were made in the
000s, because considerable progress had been made with
djunctive antithrombotic therapy and, in particular, the
ombined use of aspirin and thienopyridine therapy and
ntravenous glycoprotein IIb/IIIa inhibitors. Those attempts
ere made in 2 directions: improving the efficacy of PPCI
y administering fibrinolytic treatment or GP IIb/IIIa
nhibitors en route to the interventional procedure (so-
alled “facilitated” PCI); or improving the result of fibrino-
ysis by performing subsequent PCI in all or selected
atients.
acilitated PCI. A number of randomized trials have com-
ared PPCI with PCI “facilitated” by either fibrinolytic
reatment or GP IIb/IIIa inhibitors or both. A meta-
nalysis published in 2006 showed that, although more
atients assigned to facilitated PCI had initial Thrombolysis
n Myocardial Infarction flow grade 3, there was no clinical
enefit, compared with PPCI (15). Recently, facilitated PCI
as evaluated in 2 large randomized trials. The ASSENT-4
Assessment of the Safety and Efficacy of a New Treatment
trategy for Acute Myocardial Infarction) PCI trial com-
ared PPCI with PCI immediately preceded by tenecteplase
nd was interrupted prematurely because an excess of events
as observed in the facilitated arm, and this despite the fact
hat more patients had an open infarct-related artery before
he angioplasty procedure (16). Two factors might have
xplained these findings: first, concomitant antithrombotic
herapy might have been insufficient in the tenecteplase arm
f the trial, with the use of a low dose of heparin and
inimal use of GP IIb/IIIa inhibitors; and second, PCI was
erformed very soon after administration of fibrinolytic
reatment, at a time when platelet reactivity was still
ncreased. Both factors might have played a role in the
xcess reinfarction rate observed in the facilitated arm. In
he FINESSE (Facilitated Intervention with Enhanced
eperfusion Speed to Stop Events) trial, patients were
andomized in a 1:1:1 fashion to PPCI with in-lab abcix-
mab, upfront abciximab-facilitated PPCI, or half-dose
eteplase/abciximab-facilitated PCI (17). Although ST-
egment resolution was more frequently observed in the
ombination-facilitated PCI, no difference was found in the
rimary outcome of the trial (death, late ventricular fibril-
ation, cardiogenic shock, or congestive heart failure at 90
ays).
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903escue PCI. Several trials addressed the question of the
enefit of coronary angiography and PCI after fibrinolytic
reatment. The REACT (Rescue Angioplasty versus Con-
ervative Treatment or Repeat Thrombolysis) trial showed
hat, in patients who had failed fibrinolytic therapy, rescue
CI was better than a conservative approach or repeated
brinolysis (18).
ystematic PCI and timing of PCI after ﬁbrinolysis. Further-
ore, the role of systematic PCI within 24 h of fibrinolysis
as investigated in the GRACIA-1 (Grupo de Analisis de
a Cardiopatia Isquemica Aguda) trial (19), the CAPITAL-
MI (Combined Angioplasty and Pharmacological Inter-
ention versus Thrombolysis Alone in Acute Myocardial
nfarction) trial (20), the SIAM-III (Southwest German
nterventional Study in Acute Myocardial Infarction) (21),
nd in the larger CARESS-in-AMI (Combined Abciximab
Eteplase Stent Study in Acute Myocardial Infarction) trial
22). In all instances, a strategy of systematic PCI after
ntravenous fibrinolytic treatment yielded better results than
onservative management. The CARESS-in-AMI trial
22) demonstrated that a strategy of immediate PCI was
etter than the standard of rescue-only angioplasty after
brinolysis, with a significant and marked reduction in the
rimary end point of death, reinfarction, or refractory
schemia at 30 days (10.7% vs. 4.4%, p  0.005). More
ecently, the TRANSFER-AMI (Trial of Routine ANgio-
lasty and Stenting after Fibrinolysis to Enhance Reperfusion
n Acute Myocardial Infarction) enrolled 1,030 patients12 h
fter acute MI who received fibrinolytic treatment and were
andomly assigned to transfer for angioplasty within 6 h or to
strategy limiting emergency angiography to rescue angio-
lasty, associated with elective angiography in those not
eeding rescue angioplasty. The primary results (23)
howed there was no difference in mortality between the
tandard and pharmacoinvasive treatment (3.4% vs. 4.5%,
 0.39), but the composite end point of death, MI,
ecurrent ischemia, new or worsening heart failure, or
ardiogenic shock was strongly in favor of the pharmaco-
nvasive strategy (11.0% vs. 17.2%, p  0.004).
The WEST (Which Early ST-segment elevation myo-
ardial infarction Therapy) study (24) further strengthens
his concept by suggesting that rapidly applied pharmaco-
ogical reperfusion with follow-up (rescue and routine) PCI
ithin 24 h produces results equivalent to PPCI.
he Importance of Time Delays
he success of reperfusion in STEMI is dependent on the
ime of administration. For all recent guidelines, including
he American College of Cardiology/American Heart As-
ociation guidelines (25), time delays are central in the
ecision-making process. However, registry data show that
he 30-min door-to-needle and 90-min door-to-balloon
DB) time goals are extremely difficult to achieve. In iarticular, DB times are often much longer in clinical
ractice than in randomized controlled trials, because trans-
er of patients for PCI, local factors (weather conditions,
eographic location, staff initially involved, and so forth), or
oor management strategies can lead to long delays (26). An
nalysis of the NRMI (National Registry of Myocardial
nfarction) 3/4 data demonstrated that only 4.2% of patients
ndergoing PPCI achieve a DB time 90 min (27).
espite continued efforts, the most recent data from the
RACE (Global Registry of Acute Coronary Events) failed
o document any meaningful improvement in time delays
or reperfusion therapy between 2000 and 2005: the pre-
ospital delay time was slightly longer in the latest time
eriod (133 min during July 2005 to June 2006) compared
ith the earliest one (120 min during April 1999 to June
000); times from admission to the hospital to PPCI or
brinolysis decreased, however (from 99 to 80 min for PPCI
nd from 40 to 34 min for fibrinolysis) (26).
Time delays are also crucial to determine the best
eperfusion strategy: the superiority of PPCI over fibrino-
ysis exists only as far as the time to reperfusion is not
xceedingly increased by opting for PCI rather than the
impler approach of intravenous fibrinolysis.
From their review of the NRMI database, Pinto et al.
28) found that the equipoise between the 2 reperfusion
echniques varied according to time from symptom onset,
ocation of MI, and age of the patient. Primary PCI yielded
etter results than fibrinolysis when the excess time delay for
elivering reperfusion therapy (PCI-related delay) did not
xceed 114 min on average; however, the benefit of PCI was
ost when the PCI-related delay was longer than 40 min for
atients younger than 65 years of age with an anterior MI
resenting within 2 h of symptom onset, whereas a PCI-
elated delay of 179 min still yielded equivalent results for
oth reperfusion techniques in patients over 65 years of age,
ith a nonanterior MI seen more than 2 h from symptom
nset.
rganization of Care: Bringing Treatment to
he Patient or Bringing the Patient to Treatment
he current challenge is therefore to organize care in order
o optimize the implementation of early reperfusion therapy
n patients developing STEMI, with a tailored approach for
ach patient. Two main directions can be used, depending
n the local environment: either bringing the patient to
reatment (i.e., bringing the patient in a timely manner to a
atheterization laboratory where primary angiography will
e performed), or bringing the treatment to the patient (i.e.,
dministering intravenous fibrinolytic treatment in the pre-
ospital setting). Both methods can be jointly used, as
oncomitant antithrombotic medications can be adminis-
ered in the pre-hospital setting, en route to the catheter-
zation laboratory. In the past few years, the results achieved
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904ith several types of networks have been reported with
atisfactory clinical results and emphasize that there is no
nique way to deliver reperfusion therapy for STEMI
atients.
he Vienna experience. In March 2003, an initiative with
he goal of optimizing the organization of reperfusion
trategies was started in the city of Vienna (29). The system
rganized a network of catheterization laboratories, with a
entral triage organization via the Viennese Ambulance
ystem. An algorithm derived from the 2003 European
uidelines recommended bringing the patient to a PCI-
apable hospital as soon as possible, in conjunction with
ecommendations to initiate thrombolytic therapy, prefera-
ly before arrival at the hospital if PPCI could not be offered
n a timely fashion, particularly in the case of patients with
duration of symptoms of 2 h. Concurrently, a prospec-
ive registry was established for control and quality assur-
nce purposes. Results of the Vienna STEMI registry
ndicate that there was a shift in terms of the types of
eperfusion therapy used from 2002 to 2004, with a decline
n the use of fibrinolysis, and an increase in the use of PPCI.
mportantly, the new organization resulted in a marked
ecrease in the proportion of patients who received no
eperfusion therapy. However, even in this well-organized
etwork system, a minority of patients who underwent
PCI had the procedure within 2 h from symptom onset; in
ontrast, 50% of those treated with fibrinolysis had treat-
ent within 2 h. After thrombolytic therapy, 91% of
atients overall underwent coronary angiography, 50% im-
ediately, and 41% within 1 to 5 days of fibrinolysis.
verall, mortality rates for patients who did not receive
eperfusion therapy were strikingly higher than in those
atients who received PPCI or thrombolytic therapy (18.4%
s. 8.1% and 8.2%, respectively). In patients who were
reated early (0 to 2 h from onset of pain), there was a slight
dvantage for thrombolytic therapy over PPCI (5.1% vs.
.8%), whereas the mortality advantage favored PPCI if the
elay was between 2 and 6 h (6.7% vs. 10.6%) or 6 and 12 h
12.5% vs. 28.6%).
he French experience with the Service d’Aide Médicale
rgente (SAMU) system. The SAMU is a nationwide system
mplemented slightly more than 20 years ago, with a unique
ationwide call number. There is 1 SAMU medical re-
ponse center for each French administrative region, which
ispatches 1 of several mobile intensive care units (MICUs)
hat can provide critical care in the field and during
ransport. By French law, each MICU team must include a
hysician, usually an anesthesiologist or emergency physi-
ian, a nurse, and a driver trained as an emergency medical
echnician. Management on scene by the MICU team and
recise notification to the medical center of the patient
tatus allow direct admission to the most appropriate
etting.The FAST-MI (French registry of Acute ST-segment
levation or non–ST-segment elevation Myocardial Infarc-
ion) evaluated all patients hospitalized for acute MI in an
ntensive care unit in France; approximately 60% of all
rench hospitals participated (30). For patients seen within
2 h of symptom onset, first medical contact was through
AMU in approximately 40% of the cases, whereas 30% of
he patients initially called their general practitioner, and
5% of patients went directly to the emergency room.
owever, the proportion of patients transported by the
AMU was nearly two-thirds, because in many instances
he SAMU was called by the first medical party involved. In
erms of reperfusion strategies, 21% of patients received
re-hospital fibrinolysis, 11% received in-hospital fibrino-
ysis, 38% underwent PPCI, and 30% received no reperfu-
ion therapy. The use and type of reperfusion therapy were
ependent on the use of the SAMU system. All patients
eceiving pre-hospital thrombolytic therapy had been trans-
orted by the SAMU. Of patients having called the SAMU
nitially, 18% had no reperfusion therapy; in contrast, when
he first medical contact was not the SAMU, 36% received
o reperfusion therapy (The FAST-MI Registry, unpub-
ished data, July 2009) (Fig. 1). Median time from first call
o reperfusion was 45 min for pre-hospital lysis and 166 min
or PPCI; even in patients who called the SAMU directly,
edian time from call to PPCI was 130 min. Because the
verage time for the SAMU to reach the patients after being
alled is on the order of 20 to 25 min, median time to PPCI
fter the first electrocardiogram (ECG) is still long (100 to
10 min), whereas time to initiation of fibrinolytic treat-
ent is much shorter (20 to 25 min), thanks to the use of
re-hospital fibrinolysis.
It was also observed that the number of parties involved
efore hospital admission was a determinant of both time to
Figure 1. Use of Reperfusion Therapy According to Initial Pathway in the
FAST-MI Registry
Patients having called the Service d’Aide Médicale Urgente (SAMU) directly
had a higher rate of pre-hospital ﬁbrinolysis, and fewer had no reperfusion
therapy. FAST-MI  French registry of Acute ST-segment elevation or non–
ST-segment elevation Myocardial Infarction; PCI  percutaneous coronary
intervention; Rx  therapy; STEMI  ST-segment elevation myocardial
infarction.
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905eperfusion and clinical outcomes (Table 1) (The FAST-MI
egistry, unpublished data, July 2009).
When PPCI is not performed, the most widely used
trategy in France is a pharmaco-invasive approach, with
6% of patients undergoing coronary angiography after
ntravenous fibrinolysis (31). Approximately 85% of patients
ndergo subsequent PCI (87% after pre-hospital fibrinoly-
is), and 58% of these patients undergo PCI within 24 h of
he administration of fibrinolysis. In-hospital mortality was
.3% for fibrinolysis and 5.0% for PPCI. In patients
eceiving fibrinolysis, 30-day mortality was 9.2% when PCI
as not used and 3.9% when PCI was subsequently per-
ormed. Overall, no difference was observed according to the
ime lag between administration of fibrinolysis and PCI;
owever, these seemingly uniform outcomes result from
pposite trends: in patients in whom PCI is performed as a
ystematic policy, mortality is lower when PCI is performed
fter the first hours, whereas in patients in whom PCI is
ndicated because of persisting or recurring symptoms (res-
ue PCI), mortality is higher when PCI is performed after
longer time lag.
One-year survival was 94% for fibrinolysis and 92% for
PCI (p  0.31); after propensity score matching, 1-year
urvival was 94% and 93%, respectively. These results
onfirm that, in selected patients presenting early after
ymptom onset, fibrinolytic treatment followed by system-
tic angiography and—when needed—PCI is a true alter-
ative to PPCI.
The satisfactory results of pre-hospital fibrinolysis when
sed in a timely fashion in physician-staffed ambulances are
onfirmed by the German data from the PREMIR (Pre-
ospital Myocardial Infarction Registry), showing that in-
ospital mortality was not different from that of PPCI (32).
ikewise, the Israeli experience from the city of Haifa
howed very favorable results with wide use of intravenous
brinolysis followed by an aggressive policy of rescue PCI
nd early intervention (33): in this registry, 25% of the
atients treated with fibrinolysis had rescue PCI, and 92%
nderwent coronary angiography during the same hospital
tay, with 79% undergoing PCI. The 30-day mortality was
.7%, and 1-year mortality was 6.7%. Of note, mortality was
ower in the patients receiving fibrinolysis within 150 min of
Table 1. Impact on Time Delays and 30-Day Mortality of the Number of
Medical Parties Involved Before Hospital Admission in the French
FAST-MI Registry
0 or 1 Party 2 Parties >3 Parties
Median time from ﬁrst call
to reperfusion (range)
100 (50–170) 122 (60–201) 155 (80–270)
30-day mortality 5.5% 7.1% 12.1%
FAST-MI French registry of Acute ST-segment elevation or non–ST-segment elevationMyocar-
dial Infarction.ymptom onset and in those undergoing subsequent PCI. hhe same findings are reported from the Polish Wielkopol-
ka registry, in which thrombolytic treatment with tissue
lasminogen activator followed by PCI in 26% of the
atients provided results that compared to those of PPCI in
atients with onset of chest pain 4 h (34).
Overall, the European experience suggests that a phar-
acoinvasive strategy combining fibrinolysis followed by
arly coronary angiography (with PCI when deemed neces-
ary) yields excellent clinical results and that, in selected
atients, it can constitute an alternative to PPCI.
ecent experiences from North America. The organization
f care in North America is confronted with the difficulty of
ealing with the long distance that separates many patients
rom tertiary centers capable of providing “24/7” emergency
nterventions. Therefore transfer must be envisaged in such
ases, and very encouraging results have been recently
eported from regional systems set up to provide optimal
are for STEMI patients, wherever the MI occurred. The
innesota regional system of care (35) designed specific
herapeutic protocols for patients with STEMI presenting
o hospitals far from the main PCI center; patients present-
ng at hospitals within 60 miles of the tertiary center (zone
) were directly transferred to the catheterization laboratory
f the tertiary center; patients presenting at hospitals 60 to
10 miles from the tertiary center (zone 2) received one-
alf-dose tenecteplase en route to the PCI center. Personnel
t the primary care hospitals were specially trained, and
CGs were faxed to the PCI center before transfer. In the
ase of inclement weather or other anticipated delays,
atients from zone 1 received one-half-dose tenecteplase,
nd those from zone 2 received full-dose lytics. Thirty-day
ortality was similar in patients presenting directly at the
ertiary center (4.4%) and in those from zone 1 (4.7%) and
one 2 (5.2%).
A similar experience was reported with the Mayo Clinic
TEMI protocol (36). A network was organized between a
ertiary hospital with 24/7 PCI capability and primary care
nstitutions located in a radius for which the maximum
ransfer time did not exceed 90 min. The primary reperfu-
ion strategy at local hospitals was fibrinolysis (full dose) in
atients presenting 3 h of symptom onset and PPCI in
hose presenting 3 h. For PPCI, the emergency depart-
ent at the tertiary hospital was bypassed to avoid losing
ime; patients with fibrinolysis were evaluated by a cardiol-
gist upon arrival, those without signs of reperfusion un-
erwent immediate rescue PCI, and coronary angiography
as performed on a systematic basis in all other patients 24
o 48 h later. In-hospital mortality was 6.6% in patients
dmitted directly to the tertiary center, 5.7% in those
dmitted to regional centers and treated with PPCI, and
.1% in those admitted to regional centers and treated with
brinolysis.
Similar efforts have been made in North Carolina and
ave led to marked reductions in times to reperfusion in
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906atients initially admitted to primary care hospitals; in spite
f these improvements, however, no further reduction in
arly mortality, compared with historic control subjects, was
bserved in a recently reported series of 1,164 patients (37).
A recent review of 10 organizations of 72 hospitals
eographically spread across the U.S. but sharing a common
se of pre-hospital triage methods showed that DB times
90 min could be achieved in 86% of the patients with a
re-hospital STEMI diagnosis and that ECG-to-balloon
imes were 90 min in 68% of the patients (38).
Table 2. Specificities of 4 Different Systems of Care With Both PPCI and
Pharmacoinvasive Strategies for STEMI Patients
Location (Ref. #) Specificities
Vienna (29) Citywide system of care. Unique call number.
Physician-staffed ambulances sent on site.
Direct dispatching to PCI hospital if estimated time to PCI
90 min or if time from symptom onset 2–3 h or if
contraindication to ﬁbrinolysis. Otherwise, ﬁbrinolysis
pre-hospital or at emergency room.
Network of 1 academic and 4 other institutions with
rotation during off-hours on weekdays (1 institution
on-call/day); the system permits that only experienced
interventional cardiologists operate while the
institution is on-call.
France (SAMU) (31) Nationwide system of care. Unique call number. One
call-center/administrative region.
Physician-staffed ambulance sent on site.
Dispatching to nearest PCI-capable institution if expected
time from contact to PCI 90 min or if
contraindications. Otherwise, pre-hospital ﬁbrinolysis
(tenecteplase or reteplase) and admission to either
nearest hospital or nearest hospital with PCI capability:
96% of patients treated with ﬁbrinolysis undergo
coronary angiography (75% within 24 h of
administration of ﬁbrinolysis).
Minneapolis (35) Regional system of care (30 institutions, 1 PCI center;
210-mile radius).
Diagnosis made at the emergency department of any of
the participating hospitals. Single phone call to PCI
hospital.
1. 11 hospitals 60 miles from PCI center:
one-half-dose tenecteplase (if no contraindication).
Direct transfer to cath lab (bypassing PCI center
emergency department).
2. 19 hospitals 60–210 miles from PCI center:
full-dose tenecteplase (if no contraindication). Direct
transfer to cath lab (bypassing PCI center
emergency department).
70% transported by helicopter; cardiac arrest in 2%
during transfer.
Mayo Clinic (36) Regional system of care (28 institutions, 1 PCI center;
150-mile radius).
Diagnosis made at regional center. Single phone call to
PCI hospital.
1. If symptoms 3 h: full-dose ﬁbrinolysis, if no
contraindication (reteplase or tenecteplase).
Evaluation on admission at PCI center; if no
reperfusion: rescue PCI, otherwise, systematic
coronary angiography 24–48 h after admission.
2. If symptoms 3 h: PPCI. Direct transfer to cath lab
(bypassing PCI center emergency department).
PPCI primary percutaneous coronary intervention; SAMU Service d’Aide Médicale Urgente;aSTEMI ST-segment elevation myocardial infarction.All systems of care had in common the fact that the
atheterization laboratory could be activated by a single call
rom the initial emergency physicians in charge of the
atients. In addition, all continuously monitored the clinical
esults achieved (Table 2).
ther organizational issues: place of admission, time of
dmission, time delays. Beyond the choice of the reperfu-
ion strategy, STEMI networks allow better organization of
he initial management of patients. Important factors lead-
ng to improved delivery of reperfusion therapy have been
videnced from a large survey of 365 institutions from the
.S. (39). These included direct activation of the catheter-
zation laboratory by the emergency physicians, with a single
all number to activate the catheterization laboratory; hav-
ng staff arriving at the catheterization laboratory within 20
in after being paged; or having an attending cardiologist
n site.
Pre-hospital diagnosis of STEMI leads to shortened
imes to reperfusion (40–42). Pre-hospital triage can be
ade either by physicians, as is the case in France with the
AMU physician-staffed emergency medical system, or
ith specially trained paramedics (42). Teletransmission of
he ECG recorded in the field can be helpful to achieve a
aster initial diagnosis and has been shown to reduce time to
nitiation of reperfusion therapy (43).
Protocols can be implemented to reduce the time be-
ween hospital admission and recording and interpretation
f the first ECG (if that has not been done before hospital
dmission). Once the diagnosis is made, it is also essential to
acilitate admission to the catheterization laboratory and to
ave staff at the catheterization laboratory available as
uickly as possible. In the French experience, bypassing the
mergency room was associated with higher rates of reper-
usion therapy, reductions in time delays before initiation of
eperfusion therapy, and improved survival (44).
Finally, special efforts are warranted for the organization
f care for patients admitted “off-hours.” The Get with the
uidelines Committee observed that there were fewer
PCI procedures and overall revascularizations and longer
B times in patients presenting off-hours (45). However,
here was no difference in mortality in patients admitted on-
ersus off-hours, a finding that was confirmed in a large
wiss registry including 12,480 patients, one-half of whom
ere admitted off-hours (in-hospital mortality was 8.5% in
atients admitted during routine working hours, and 8.8%
n those admitted off-hours) (46).
onclusions
CI is central in the management of acute STEMI.
lthough, in optimal conditions, PPCI is the undisputed
referred therapeutic approach, organizational difficulties
re numerous and have led to alternative reperfusion strat-
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907gies, among which the pharmacoinvasive approach is the
ost attractive.
Therefore, one of the key questions for policymakers is to
ecide whether to push for more local hospitals with PCI
apability or to promote tertiary (quaternary?) centers with
he use of a more pharmacoinvasive approach for those
atients at a distance. Beyond cost issues (installation of
atheterization laboratories in smaller hospitals supposes
dditional costs for both equipment and the medical/
aramedical environment to run the laboratory), “spreading”
4/7 catheterization laboratories all over the country—many
f which will have to treat only a few STEMI patients—is
ikely to result in less-than-optimal care for patients treated
ith PPCI overall. A recent analysis from the New York
tate PCI registry shows that early mortality (adjusted for
he registry risk score) increased from 3.32% in hospitals
ith an annual volume 75 cases to 5.37% in institutions
ith an annual volume 25 cases, representing a 61%
elative risk increase, potentially offsetting any possible
enefit compared with an initial pharmacologic strategy
47). In the same analysis, individual physician volume was
lso an important determinant of outcome; in this respect,
he organization of care in Vienna, with hospitals on-call
uring off-hours only 1 day/week, ensures that only senior,
xperienced operators will manage STEMI patients. The
uestion of hospital and physician volumes of activity will be
ll the more crucial with the current decline in the incidence
f STEMI (48).
Organization of networks on the basis of the use of both
PCI and pharmacoinvasive approaches should be the most
fficacious strategy; most patients will be treated with PPCI
n large institutions within reasonable time limits, whereas
thers—living farther away from PCI centers—will be
reated with fibrinolysis first. In France, the pre-hospital,
tate-run system of care (SAMU) is the only structured
ystem available, and the patients initially managed by the
AMU are dispatched to the most readily available facili-
ies, whether state-run hospitals or private clinics; a regional
ealth agency is in charge of the organization of the network
or cardiac emergencies. In countries such as the U.S., the
xistence of competing hospital systems might constitute a
arrier to the implementation of optimal systems of care for
he population, because there might be more financial
ncentive within a hospital system to have institutions
roviding more costly technology—such as PCI—even if
hese do not constitute the best medical option. Ideally,
ublic health agencies might be the solution for design-
ng networks, harmonizing the activities of the existing
ospital systems to provide the population the best
ossible system, making the best of the 2 options for
eperfusion therapy (PPCI or pharmacoinvasive strategy)
ccording to the time required for the patient to get to a
free and operational) catheterization laboratory. Thisould probably represent a major cultural change in the
ountry of free enterprise.
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